Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 9.3% - Still a Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) shares were up 9.3% during trading on Friday . The company traded as high as $2.73 and last traded at $2.64. Approximately 1,628,524 shares were traded during trading, a decline of 25% from the average daily volume of 2,165,084 shares. The stock had previously closed at $2.41.

Wall Street Analyst Weigh In

TSHA has been the subject of a number of analyst reports. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies has a consensus rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

The stock has a fifty day moving average of $1.61 and a 200-day moving average of $1.81. The firm has a market capitalization of $410.11 million, a P/E ratio of 3.17 and a beta of 0.90. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in TSHA. Avoro Capital Advisors LLC lifted its stake in Taysha Gene Therapies by 7.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after acquiring an additional 1,349,999 shares during the last quarter. Octagon Capital Advisors LP lifted its stake in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after purchasing an additional 5,877,778 shares during the last quarter. Vanguard Group Inc. grew its holdings in Taysha Gene Therapies by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after purchasing an additional 641,305 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies during the fourth quarter worth approximately $8,650,000. Finally, Geode Capital Management LLC increased its position in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after buying an additional 9,591 shares during the last quarter. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.